UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2316-2
Program Prior Authorization/Medical Necessity
Medication Xdemvy™ (lotilaner) ophthalmic solution 0.25%
P&T Approval Date 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Xdemvy (lotilaner) ophthalmic solution 0.25% is indicated for the treatment of Demodex
blepharitis.
2. Coverage Criteriaa:
A. Authorization
1. Xdemvy will be approved based on all of the following criteria:
a. Diagnosis of Demodex blepharitis
-AND-
b. Patient demonstrates one of the following signs of Demodex infestation
1) Cylindrical cuff at the root of the eyelashes
2) Lid margin erythema
3) Eyelash anomalies (eyelash misdirection)
-AND-
c. Patient demonstrates two of the following symptoms of Demodex infestation
1) Itching/Burning
2) Foreign body sensation
3) Crusting/matter lashes
4) Blurry vision
5) Discomfort/irritation
-AND-
d. Patient is practicing good eye-lid hygiene (e.g., non-prescription tree-tea oil)
-AND-
e. Prescribed by or in consultation with one of the following:
1) Ophthalmologist
© 2024 UnitedHealthcare Services Inc.
1
2) Optometrist
Authorization will be issued for 3 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Xdemvy [package insert]. Irvine, CA: Tarsus Pharmaceuticals, Inc. July 2023.
2. M.T Yen. Demodex Infestation. American Academy of Ophthalmology. EyeWiki. April 25,
2023.
Program Prior Authorization/Medical Necessity – Xdemvy
Change Control
Date Change
11/2023 New program
11/2024 Annual review. No changes
© 2024 UnitedHealthcare Services Inc.
2